PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
13 hedge funds and large institutions have $20.7M invested in PLx Pharma Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$7.85M |
| 2 |
BC
Broadfin Capital
New York
|
+$5.27M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.86M |
| 4 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$2.36M |
| 5 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
+$1.72M |
Top Sellers
PLXP Hedge Fund Activity: Q1 2014 in Review
13 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q1 2014, worth a combined $20.7M.
Buyers outnumbered sellers: 13 funds opened new PLXP positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $7.85M.
- 13 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $20.7M of PLx Pharma Inc. Common Stock stock for Q1 2014.
- 13 funds opened new PLx Pharma Inc. Common Stock positions in Q1 2014 and 0 closed out, a net change of +13 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q1 2014 was Kingdon Capital Management, an estimated $7.85M added.
Based on aggregated 13F filings for Q1 2014.